BIND Biosciences and Amgen Sign Agreement for the Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

Collaboration to Develop a Novel and Targeted Accurin™ Based on BIND’s Nanomedicine Platform and Amgen’s Kinase Inhibitor

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC).

CAMBRIDGE, Mass., Dec. 19, 2012 /PRNewswire via COMTEX/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Stephen Hoge, MD, currently a partner at McKinsey & Company, will join the company as Senior Vice President of Corporate Development and New Drug Concepts on January 1st, 2013. In this newly created role, Dr.

Pharmaceutical industry leader to drive company growth and strategy with initial focus on new classes of cancer therapies

Company accelerates product development with two lead programs

Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013

Follows Successful Completion of Phase 1a Clinical Study

Lead Candidate from Eleven’s AMP-Rx Product Engine for First-of-a-Kind Protein Therapeutics

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on T2Hemostasis, the first system capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument. The data were presented by researchers from the University of Pennsylvania at the 54^th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, GA.